Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
ACS Appl Mater Interfaces ; 13(30): 35494-35505, 2021 Aug 04.
Artículo en Inglés | MEDLINE | ID: mdl-34288640

RESUMEN

Polymer nanocapsules, with a hollow structure, are increasingly finding widespread use as drug delivery carriers; however, quantitatively evaluating the bio-nano interactions of nanocapsules remains challenging. Herein, poly(ethylene glycol) (PEG)-based metal-phenolic network (MPN) nanocapsules of three sizes (50, 100, and 150 nm) are engineered via supramolecular template-assisted assembly and the effect of the nanocapsule size on bio-nano interactions is investigated using in vitro cell experiments, ex vivo whole blood assays, and in vivo rat models. To track the nanocapsules by mass cytometry, a preformed gold nanoparticle (14 nm) is encapsulated into each PEG-MPN nanocapsule. The results reveal that decreasing the size of the PEG-MPN nanocapsules from 150 to 50 nm leads to reduced association (up to 70%) with phagocytic blood cells in human blood and prolongs in vivo systemic exposure in rat models. The findings provide insights into MPN-based nanocapsules and represent a platform for studying bio-nano interactions.


Asunto(s)
Sangre/metabolismo , Estructuras Metalorgánicas/química , Nanocápsulas/química , Polietilenglicoles/química , Pirogalol/análogos & derivados , Animales , Citometría de Flujo/métodos , Oro/química , Oro/metabolismo , Oro/farmacocinética , Oro/toxicidad , Humanos , Masculino , Nanopartículas del Metal/química , Nanopartículas del Metal/toxicidad , Estructuras Metalorgánicas/metabolismo , Estructuras Metalorgánicas/farmacocinética , Estructuras Metalorgánicas/toxicidad , Ratones , Nanocápsulas/toxicidad , Tamaño de la Partícula , Polietilenglicoles/metabolismo , Polietilenglicoles/farmacocinética , Polietilenglicoles/toxicidad , Pirogalol/metabolismo , Pirogalol/farmacocinética , Pirogalol/toxicidad , Células RAW 264.7 , Ratas Sprague-Dawley
2.
Mol Nutr Food Res ; 61(12)2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28891114

RESUMEN

SCOPE: To understand the mechanism by which green tea lowers the risk of dementia, focus was placed on the metabolites of epigallocatechin gallate (EGCG), the most abundant catechin in green tea. Much of orally ingested EGCG is hydrolyzed to epigallocatechin (EGC) and gallic acid. In rats, EGC is then metabolized mainly to 5-(3',5'-dihydroxyphenyl)-γ-valerolactone (EGC-M5) and its conjugated forms, which are distributed to various tissues. Therefore, we examined the permeability of these metabolites into the blood-brain barrier (BBB) and nerve cell proliferation/differentiation in vitro. METHODS AND RESULTS: The permeability of EGC-M5, glucuronide, and the sulfate of EGC-M5, pyrogallol, as well as its glucuronide into the BBB were examined using a BBB model kit. Each brain- and blood-side sample was subjected to liquid chromatography tandem-mass spectrometry analysis. BBB permeability (%, in 0.5 h) was 1.9-3.7%. In human neuroblastoma SH-SY5Y cells, neurite length was significantly prolonged by EGC-M5, and the number of neurites was increased significantly by all metabolites examined. CONCLUSION: The permeability of EGC-M5 and its conjugated forms into the BBB suggests that they reached the brain parenchyma. In addition, the ability of EGC-M5 to affect nerve cell proliferation and neuritogenesis suggests that EGC-M5 may promote neurogenesis in the brain.


Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Catequina/metabolismo , Lactonas/farmacocinética , Neuritas/efectos de los fármacos , Té/química , Catequina/análogos & derivados , Catequina/farmacocinética , Catequina/farmacología , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Humanos , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/metabolismo , Pirogalol/farmacocinética
3.
Arch Toxicol ; 91(2): 713-734, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27334372

RESUMEN

The present study describes physiologically based kinetic (PBK) models for the alkenylbenzene myristicin that were developed by extension of the PBK models for the structurally related alkenylbenzene safrole in rat and human. The newly developed myristicin models revealed that the formation of the proximate carcinogenic metabolite 1'-hydroxymyristicin in liver is at most 1.8 fold higher in rat than in human and limited for the ultimate carcinogenic metabolite 1'-sulfoxymyristicin to (2.8-4.0)-fold higher in human. In addition, a comparison was made between the relative importance of bioactivation for myristicin and safrole. Model predictions indicate that for these related compounds, the formation of the 1'-sulfoxy metabolites in rat and human liver is comparable with a difference of <2.2-fold over a wide dose range. The results from this PBK analysis support that risk assessment of myristicin may be based on the BMDL10 derived for safrole of 1.9-5.1 mg/kg bw per day. Using an estimated daily intake of myristicin of 0.0019 mg/kg bw per day resulting from the use of herbs and spices, this results in MOE values for myristicin that amount to 1000-2700, indicating a priority for risk management. The results obtained illustrate that PBK modeling provides insight into possible species differences in the metabolic activation of myristicin. Moreover, they provide an example of how PBK modeling can facilitate a read-across in risk assessment from a compound for which in vivo toxicity studies are available to a related compound for which tumor data are not reported, thus contributing to alternatives in animal testing.


Asunto(s)
Compuestos de Bencilo/farmacocinética , Dioxolanos/farmacocinética , Modelos Teóricos , Pirogalol/análogos & derivados , Activación Metabólica , Derivados de Alilbenceno , Animales , Carcinógenos/farmacocinética , Humanos , Inactivación Metabólica , Cinética , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Microsomas/efectos de los fármacos , Microsomas/metabolismo , Oxidación-Reducción , Pirogalol/farmacocinética , Ratas Sprague-Dawley , Medición de Riesgo/métodos , Safrol/farmacocinética
4.
Planta Med ; 82(13): 1192-201, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27420350

RESUMEN

Tryptanthrin and (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolinone (indolinone) were recently isolated from Isatis tinctoria as potent anti-inflammatory and antiallergic alkaloids, and shown to inhibit COX-2, 5-LOX catalyzed leukotriene synthesis, and mast cell degranulation at low µM to nM concentrations. To assess their suitability for oral administration, we screened the compounds in an in vitro intestinal permeability assay using human colonic adenocarcinoma cells. For exact quantification of the compounds, validated UPLC-MS/MS methods were used. Tryptanthrin displayed high permeability (apparent permeability coefficient > 32.0 × 10(-6) cm/s) across the cell monolayer. The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions. For indolinone, a low recovery was found in the human colon adenocarcinoma cell assay. High-resolution mass spectrometry pointed to extensive phase II metabolism of indolinone (sulfation and glucuronidation). Possible cardiotoxic liability of the compounds was assessed in vitro by measurement of an inhibitory effect on human ether-a-go-go-related gene tail currents in stably transfected HEK 293 cells using the patch clamp technique. Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM). The analysis of compounds using various in silico methods confirmed favorable pharmacokinetic properties, as well as a slight inhibition of the human ether-a-go-go-related gene potassium channel at micromolar concentrations.


Asunto(s)
Antialérgicos/farmacocinética , Antiinflamatorios no Esteroideos/farmacocinética , Indoles/farmacocinética , Pirogalol/análogos & derivados , Quinazolinas/farmacocinética , Células CACO-2 , Permeabilidad de la Membrana Celular , Cromatografía Líquida de Alta Presión/métodos , Células HEK293 , Humanos , Absorción Intestinal , Isatis/química , Pirogalol/farmacocinética , Espectrometría de Masas en Tándem
5.
J Ethnopharmacol ; 155(2): 1134-40, 2014 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-25046827

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Acorus tatarinowii Schott (AT), belong to the family Araceae, is perennial herbaceous plant mainly present in China, Japan and India. The rhizomes of AT have been used as a famous traditional Chinese medicine for the treatment of central nervous system related diseases. AIM OF THE STUDY: A selective, accurate and sensitive method using gas chromatography-mass spectroscopy (GC-MS) for the simultaneous determination and pharmacokinetic study of ß-asarone, α-asarone, elemicin and cis-methyl isoeugenol in rat plasma was developed and validated. MATERIALS AND METHODS: The GC-MS system was operated under selected ion monitoring (SIM) mode. The samples were prepared by protein precipitation with acetonitrile after being spiked with an internal standard (1-naphthol). The GC separation was achieved on a DB-1701 column (60 m × 0.25 mm ID, and 0.25 µm film thickness). RESULTS: The current GC/MS assay was validated for linearity, intra-day and inter-day precisions, accuracy, extraction recovery and stability. The analyte calibration curves were linear over a wide concentration range and the lowest limit of quantifications (LLOQ) were 5.53 ng/mL (ß-asarone), 6.50 ng/mL (α-asarone), 3.10 ng/mL (elemicin) and 7.60 ng/mL (cis-methyl isoeugenol). After oral administration 0.9 g /Kg of AT rhizomes, the maximum plasma concentration (Cmax) was 2508.6±498.7 ng/mL for ß-asarone, 257.5±37.1 ng/mL for α -asarone, 345.5±33.4 ng/mL for elemicin and 452.7±59.1 ng/mL for cis-methyl isoeugenol, respectively. The time to reach the maximum plasma concentration (Tmax) was 1.42±0.18 h for ß-asarone, 1.58±0.19 h for α -asarone, 1.67±0.24 h for elemicin and 1.75±0.38 h for cis-methyl isoeugenol, respectively. CONCLUSION: This paper described a simple, sensitive and validated GC-MS method for simultaneous determination of four phenylpropanoids in rat plasma after oral administration of the essential oil of AT rhizomes and investigated on their pharmacokinetics studies as well.


Asunto(s)
Acorus/química , Anisoles/farmacocinética , Pirogalol/análogos & derivados , Administración Oral , Derivados de Alilbenceno , Animales , Anisoles/aislamiento & purificación , Cromatografía de Gases y Espectrometría de Masas/métodos , Masculino , Medicina Tradicional China , Aceites Volátiles/aislamiento & purificación , Aceites Volátiles/farmacocinética , Pirogalol/aislamiento & purificación , Pirogalol/farmacocinética , Ratas , Ratas Wistar , Rizoma
6.
Berl Munch Tierarztl Wochenschr ; 113(3): 108-11, 2000 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-10763554

RESUMEN

Pyrogallol (1, 2, 3-trihydroxybenzene), the decomposition product of hydrolysable tannins in oak bark, leaves and acorns, is suspected to be poisonous to animals. The aim of our investigations was to correlate clinical signs and pathological findings with pyrogallol concentrations in organs of poisoned and healthy animals. In a field study, pyrogallol concentrations were determined in liver, kidney, and rumen from seven cattle. In a herd of twelve cows, five animals suffered from hemorrhagic diarrhea, anorexia, weakness, rumen stasis, dyspnoea, and colic symptoms. Death was observed in five cows within five weeks after repeated intake of green acorns and oak leaves. Toxicological analyses of rumen content, liver, and kidney specimens of one cattle confirmed the suspicion of pyrogallol contamination. In this animal, values ranged from 6 to 13 ng pyrogallol per gram specimen. In control cattle, concentrations were clearly lower than in perished cattle. Under antioxidative work-up conditions, detection limit was 0.6 ng/g in rumen content and 1.0 ng/g in liver and kidney, respectively.


Asunto(s)
Enfermedades de los Bovinos/metabolismo , Enfermedades Transmitidas por los Alimentos/veterinaria , Contenido Digestivo/química , Riñón/metabolismo , Hígado/metabolismo , Plantas Tóxicas , Pirogalol/farmacocinética , Rumen/fisiología , Alimentación Animal , Animales , Bovinos , Femenino , Enfermedades Transmitidas por los Alimentos/metabolismo , Pirogalol/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...